Sanctuary Advisors LLC Purchases New Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Sanctuary Advisors LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 20,830 shares of the biotechnology company’s stock, valued at approximately $1,698,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ARWR. Royal Bank of Canada grew its holdings in Arrowhead Pharmaceuticals by 30.2% during the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after buying an additional 10,496 shares in the last quarter. AQR Capital Management LLC purchased a new position in Arrowhead Pharmaceuticals during the 1st quarter worth $514,000. Goldman Sachs Group Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after acquiring an additional 447,456 shares in the last quarter. Empowered Funds LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 979 shares during the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Arrowhead Pharmaceuticals by 1,339.5% during the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 15,123 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARWR has been the subject of several analyst reports. Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price objective for the company. Royal Bank Of Canada boosted their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. JPMorgan Chase & Co. increased their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Finally, Sanford C. Bernstein lifted their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.33.

Insiders Place Their Bets

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director owned 31,600 shares of the company’s stock, valued at approximately $2,747,936. This represents a 5.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $89.12 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $21.06 and a 1 year high of $95.49. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The stock’s fifty day moving average price is $83.44 and its two-hundred day moving average price is $73.29. The firm has a market cap of $12.55 billion, a PE ratio of -39.61 and a beta of 1.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The company had revenue of $75.25 million for the quarter, compared to analysts’ expectations of $44.17 million. During the same quarter in the prior year, the company earned ($1.26) EPS. The company’s revenue was up 171.0% on a year-over-year basis. On average, equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.